BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis At 46th European Cystic Fibrosis Conference
Portfolio Pulse from Benzinga Newsdesk
BiomX Inc. (NYSE:PHGE) will present Part 1 data from its Phase 1b/2a study evaluating BX004 for the treatment of chronic Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients at the 46th European Cystic Fibrosis Conference.
May 31, 2023 | 7:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BiomX's presentation of Phase 1b/2a study data on BX004 at the 46th ECFC may positively impact its stock price.
The presentation of positive data from the Phase 1b/2a study on BX004 at a major conference like the 46th ECFC can generate interest and optimism among investors, potentially leading to an increase in BiomX's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100